IP Library › Granted Patent US 7,169,387
Granted Patent B2
US 7,169,387 · App. 10/916,141 · Granted Jan 30, 2007

Antagonists of tweak and of tweak receptor and their use to treat immunological disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,169,387
App. No.
10/916,141
Granted
Jan 30, 2007
Kind
B2
Abstract

The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders.

Claims (18)

1. A method for treating or reducing the severity of multiple sclerosis in a human, the method comprising the step of administering to said human a therapeutically effective amount of a blocking antibody that binds to a polypeptide consisting of SEQ ID NO:2.

2. The method of claim 1 , wherein the antibody is a monoclonal antibody.

3. The method of claim 2 , wherein the monoclonal antibody is a monoclonal antibody produced by a hybridoma.

4. The method of claim 3 , wherein the monoclonal antibody is an AB.D3 monoclonal antibody produced by a hybridoma having ATCC Accession No. HB-12622.

5. The method of claim 1 , wherein the antibody is a recombinant antibody.

6. The method of claim 1 , wherein the antibody is a humanized antibody.

7. The method of claim 6 , wherein the antibody is a humanized chimera of antibody AB.D3 produced by a hybridoma having ATCC Accession No. HB-12622.

8. The method of claim 1 , wherein the antibody comprises variable domains of antibody AB.D3 produced by a hybridoma having ATCC Accession No. HB-12622.

9. The method of claim 1 , wherein the antibody comprises a human constant domain.

10. The method of claim 1 , wherein the antibody is an IgG.

11. The method of claim 1 , wherein the antibody is administered by a parenteral, subcutaneous, or intravenous route.

12. The method of claim 1 , wherein the antibody is administered as a liquid composition.

13. The method of claim 12 , wherein the liquid composition is a sterile, isotonic composition.

14. The method of claim 5 , wherein the antibody blocks the binding of human TWEAK-Flag polypeptide to HT29 cells.

15. The method of claim 5 , wherein the antibody also binds to a polypeptide consisting of SEQ ID NO:1.

16. A method for treating or reducing the severity of multiple sclerosis, the method comprising the step of administering, to a human subject, a therapeutically effective amount of an anti-TWEAK blocking recombinant IgG that binds to a human TWEAK polypeptide consisting of SEQ ID NO:2.

17. The method of claim 16 , wherein the recombinant IgG blocks the binding of human TWEAK-Flag polypeptide to HT29 cells.

18. The method of claim 16 , wherein the recombinant IgG also binds to a polypeptide consisting of SEQ ID NO:1.

Assignments (2)
CHANGE OF NAME Recorded May 4, 2015
From: BIOGEN IDEC MA INC.
To: BIOGEN MA INC.
Reel/Frame 035571/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2005
From: RENNERT, PAUL
To: BIOGEN IDEC MA INC.
Reel/Frame 015723/0314 →